Chronic myeloid leukemia—still a few questions
Open Access
- 31 January 2004
- journal article
- review article
- Published by Elsevier in Experimental Hematology
- Vol. 32 (1) , 2-10
- https://doi.org/10.1016/j.exphem.2003.10.001
Abstract
No abstract availableKeywords
This publication has 82 references indexed in Scilit:
- Clinical decisions for chronic myeloid leukemia in the imatinib eraSeminars in Hematology, 2003
- Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: Rationale and design of phase I/II trialsSeminars in Hematology, 2003
- Imatinib mesylate in combination with other chemotherapeutic drugs: In vitro studiesSeminars in Hematology, 2003
- Molecular mechanisms of transformation by the BCR-ABL oncogeneSeminars in Hematology, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999